PHILADELPHIA, March 24, 2015 /PRNewswire/ -- ACI Clinicalannounces a new solution for Life Sciences companies facing the growing difficulty surrounding the identification and engagement of independent medical experts. With over a decade of experience building and managing a global network of medical thought leaders, ACI offers a complete solution that simplifies all aspects of the recruitment, contracting and payment process. With pressure from new regulations like the Sunshine Payments Act, clients can contact ACI today to find the expertise needed for everything from study design to clinical consulting to full service Endpoint Adjudication and Data Monitoring Committee solutions.
Common challenges in Engaging Medical Experts
Medical experts are frequently contracted by pharmaceutical, biotech and device companies to provide thought leadership expertise at various points of development and post-marketing. Experts often serve as consultants for study design and safety issues, or as members of independent data review committees.
Finding the right match for unique project needs while complying with regulations around Health Care Provider (HCP) transfers of value can bring many challenges that ACI Clinical can help to solve:
Assistance with Fair Market Value (FMV) Determinations
Although various mechanisms are in place to establish HCP value, such as MGMA reports, these rates often don't reflect the added-value of leading medical experts. Thought-leader expertise is so rare that there is no readily available published source of fair market rates for these individuals. Given ACI's long history of managing independent expert committees – from identification and vetting to negotiating rates and managing payments – ACI holds unique insight into the actual data. Clients looking for medical expert FMV payment information can turn to ACI for real-world contractual data on hourly rates of experts in over 20 countries.
Driving Diversity with the Integrated Research Model
October 16th 2024Ashley Moultrie, CCRP, senior director, DEI & community engagement, Javara discusses current trends and challenges with achieving greater diversity in clinical trials, how integrated research organizations are bringing care directly to patients, and more.
AI in Clinical Trials: A Long, But Promising Road Ahead
May 29th 2024Stephen Pyke, chief clinical data and digital officer, Parexel, discusses how AI can be used in clinical trials to streamline operational processes, the importance of collaboration and data sharing in advancing the use of technology, and more.
Carvykti Significantly Boosts Survival, MRD Negativity in Relapsed Multiple Myeloma
December 10th 2024Phase III CARTITUDE-4 trial shows Carvykti significantly improves minimal residual disease negativity rates, progression-free survival, and overall survival compared to standard therapies for patients with relapsed or refractory multiple myeloma, especially when used earlier in treatment.